Catch Imagion’s CEO, Bob Proulx, chat with 180 Markets CEO, Greg Lowe, about the future of cancer detection and how our MagSense® medical imaging technology plans to make a difference.
180 Markets is Australia’s ultimate resource for knowledge and access to all ASX capital raises.
Questions about this interview or other inquiries, please contact us.
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® HER2
MELBOURNE – Imagion Biosystems (Company, ASX: IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to provide shareholders
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance